A Phase II, multi-site, open-label, dose-titration trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of Lu AG13909 in adults with Cushing’s disease
20433A
Phase 2 other active
Quick answer
A Phase II, multi-site, open-label, dose-titration trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of Lu AG13909 in adults with Cushing’s disease for Cushing's Disease is a Phase 2 program (other) at H. Lundbeck A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- H. Lundbeck A/S
- Indication
- Cushing's Disease
- Phase
- Phase 2
- Modality
- other
- Status
- active